As the curtain closes on the Trump presidency, biotech wrestles with its future in a divided America
At 11 am after the election, Sherlock Biosciences CEO Rahul Dhanda snuck into his office and, in the couple minutes between meetings, fired off an email to his 45 employees.
Dhanda had walked in calmly at 7 am, but over the next four hours, he watched his employees slumped at their desks. The entire office had sunk under a general malaise. He asked a team member why they were so distraught. They looked up and asked: “Why are you so calm?”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.